Skip to main content
Ipsen logo

Ipsen — Investor Relations & Filings

Ticker · IPN ISIN · FR0010259150 LEI · 549300M6SGDPB4Z94P11 PA Manufacturing
Open in API
Filings indexed 1,378 across all filing types
Latest filing 2021-10-18 Regulatory Filings
Country FR France
Listing PA IPN

About Ipsen

https://www.ipsen.com/

Ipsen is a global biopharmaceutical company focused on innovation and specialty care. The company develops and commercializes transformative medicines to address high unmet medical needs in three key therapeutic areas: oncology, rare diseases, and neuroscience. By leveraging its specialized expertise and strategic partnerships, Ipsen aims to accelerate the development of new therapies and improve health outcomes for patients worldwide. Its strategy is centered on advancing science with purpose to bring innovative treatments from research and development to the market.

Recent filings

Filing Released Lang Actions
Inside Information / Operations of the issuer (acquisitions, sales...)
Regulatory Filings Classification · 1% confidence The document is a press release dated October 18, 2021, announcing an exclusive worldwide collaboration agreement between Ipsen and Accent Therapeutics regarding a pre-clinical stage METTL3-inhibitor program for oncology. It details the financial terms (up to $446m in milestones and royalties) and provides scientific background on the target (METTL3 in AML). This type of announcement, detailing a strategic partnership, licensing deal, or major R&D development, is typically classified as a general corporate announcement or a specific type of corporate action. Since it is not a formal regulatory filing like a 10-K, an earnings release (ER), or a dividend notice (DIV), and it specifically relates to business development and pipeline expansion, it fits best under the general 'Regulatory Filings' (RNS) category as a significant corporate event announcement, or potentially 'Capital/Financing Update' (CAP) due to the large potential transaction value, but RNS is the most appropriate catch-all for non-standard press releases detailing strategic deals. Given the content is a detailed announcement of a strategic deal rather than a report itself, RNS is the best fit among the provided options for a press release detailing a collaboration.
2021-10-18 English
Informations privilégiées / Opérations de l'émetteur (acquisitions, cessions...)
Capital/Financing Update Classification · 1% confidence The document is a press release dated October 18, 2021, announcing an exclusive global collaboration between Ipsen and Accent Therapeutics regarding a pre-clinical oncology R&D program targeting the METTL3 RNA modifying protein. It details the terms of the agreement (financial considerations, milestones, royalties) and provides background information on the science and the companies involved. This type of announcement, detailing a strategic partnership, financing terms, or significant business development (like licensing an asset), falls under the category of Capital/Financing Update (CAP) or potentially Regulatory Filings (RNS) if it were a mandatory disclosure without a specific category. However, since it explicitly details a major financial/licensing transaction involving potential future payments up to $446 million, it aligns best with 'Capital/Financing Update' (CAP), which covers fundraising, financing activities, or capital structure changes, as licensing deals often involve significant upfront/milestone payments. It is not an ER (Earnings Release - no quarterly results), 10-K (Annual Report), IR (Interim Report), CT (Call Transcript), or IP (Investor Presentation). It is a specific business development announcement.
2021-10-18 French
Informations privilégiées / Autres communiqués
Board/Management Information Classification · 1% confidence The document is titled "COMMUNIQUÉ DE PRESSE" (Press Release) and announces a significant management change: the appointment of Mari Scheiffele as Executive Vice President and President International Specialty Medicine, effective November 1, 2021. This content directly aligns with the definition of Board/Management Information (MANG), which covers announcements of changes in senior management. It is not a full financial report (10-K, IR), an earnings release (ER), or a proxy statement (DEF 14A/PSI).
2021-10-11 French
Inside Information / Other news releases
Board/Management Information Classification · 1% confidence The document is a press release dated October 11, 2021, announcing the appointment of a new Executive Vice President and President of Specialty Care International, Mari Scheiffele. This type of announcement, detailing changes in senior management or the board of directors, directly corresponds to the definition of 'Board/Management Information'. The document is not a full financial report (10-K or IR), an earnings release (ER), or a proxy statement (DEF 14A/PSI). Therefore, the appropriate classification is MANG.
2021-10-11 English
Total number of voting rights and capital / Information on the total number of voting rights and the number of shares making up the capital
Regulatory Filings Classification · 1% confidence The document explicitly states it provides 'Monthly information relative to the total number of voting rights and shares composing the share capital' and references French regulatory articles (AMF). This content directly relates to tracking changes in the total number of shares and voting rights, which is a key component of major shareholding notifications or capital structure updates. However, none of the specific codes (like MRQ for Major Shareholding Notification) perfectly capture this specific monthly regulatory disclosure on total voting rights, which is often a precursor or component of major holding reports. Given the options, this type of mandatory disclosure regarding the total number of shares and voting rights aligns most closely with the scope of 'Major Shareholding Notification' (MRQ) as it deals with the underlying capital structure relevant to ownership thresholds, or potentially a general 'Regulatory Filing' (RNS). Since it is a specific, recurring disclosure about the capital base and voting power, and not a general announcement, it is best classified under the category dealing with ownership changes or capital structure. Since MRQ is defined as 'Notification of changes in significant share ownership levels (crossing thresholds)', and this document provides the base numbers used for those calculations, it is a strong candidate. However, looking closely at the definitions, there is no perfect fit for a 'Total Voting Rights' disclosure. It is a regulatory filing, but not a dividend, director dealing, or earnings release. It is most similar in nature to the data underpinning MRQ, but since it is a mandatory monthly disclosure of the total capital base, it fits best under the general 'Regulatory Filings' (RNS) as a specific, recurring regulatory report that doesn't fit the other specific categories like DIV, DIRS, or MRQ (which focuses on *crossing* thresholds, not just reporting the total base). Given the highly specific nature of the content (voting rights count), and the lack of a dedicated code, RNS is the most appropriate fallback for a mandatory regulatory disclosure.
2021-10-08 English
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 1% confidence The document is titled "Information mensuelle relative au nombre total des droits de vote et d'actions composant le capital social" (Monthly information relating to the total number of voting rights and shares comprising the share capital). It explicitly references French regulatory articles (Code de Commerce and AMF General Regulation) and provides a table detailing the total number of shares and voting rights as of a specific date (September 30, 2021). This content directly relates to the structure of the company's capital and voting rights, which aligns best with the 'Share Issue/Capital Change' category (SHA) or potentially a specific regulatory filing (RNS). However, given the specific nature of reporting total voting rights and share capital structure monthly, it is a direct disclosure about capital structure changes/status. Since there is no specific code for 'Monthly Voting Rights Report', and it is a direct disclosure of capital structure data rather than an announcement of a transaction (POS) or a general regulatory filing (RNS), SHA is the closest fit for capital structure reporting, although DVA (Declaration of Voting Results) is also related to voting rights. Reviewing the definitions, SHA covers 'Share Issue/Capital Change'. This document reports the *current state* of capital and voting rights, which is a fundamental aspect of capital structure reporting. Given the options, and the focus on the total number of shares and voting rights, SHA is the most appropriate classification for this type of periodic capital structure disclosure, even if it's not a 'change' announcement, as it reports the base capital figures.
2021-10-08 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.